Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals.

ABSTRACT:

Background and objective

Midazolam is the preferred clinical probe drug for assessing CYP3A activity. We have previously shown substantial intraindividual variability in midazolam absolute bioavailability and clearance in patients with obesity before and after weight loss induced by gastric bypass or a strict diet. The objective was to describe intraindividual variability in absolute bioavailability and clearance of midazolam in healthy individuals without obesity.

Methods

This study included 33 healthy volunteers [28 ± 8 years, 21% males, body mass index (BMI) 23 ± 2.5 kg/m²] subjected to four pharmacokinetic investigations over a 2-month period (weeks 0, 2, 4, and 8). Semi-simultaneous oral (0 h) and intravenous (2 h later) midazolam dosing was used to assess ab

SUBMITTER: Kvitne KE 

PROVIDER: S-EPMC10338616 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature